FDA-cleared profile

Sonio Suspect

Sonio · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Concurrent or post-exam fetal ultrasound aid that identifies and characterizes eight abnormal findings for interpreting-physician review; not the sole basis for management.

Clinical role
Assistive concurrent or post-exam review; the interpreting physician retains responsibility and the output is not the sole basis for patient management.
Images and patients
Ultrasound · Obstetric/Fetal
Key limitation
Keep in mind: The exact validation was limited to the specified ultrasound vendors and fetal ultrasound workflow; outputs are assistive, can be Can't be analyzed, may be manually overridden, and cannot be the sole basis for management.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Concurrent or post-exam fetal ultrasound aid that identifies and characterizes eight abnormal findings for interpreting-physician review; not the sole basis for management.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Obstetric/Fetal Input: Fetal ultrasound images and examination views from supported GE, Philips, Samsung and Canon systems, uploaded or connected through the workflow.
  • Who uses it?Intended users: Physicians and trained healthcare professionals interpreting fetal ultrasound examinations.
  • What does the software produce?Output: Per-view statuses of Suspected, Not Suspected or Can't be analyzed for supported abnormal findings, with user ability to manually override the output.
  • What is its most important limitation?Key limitation: The exact validation was limited to the specified ultrasound vendors and fetal ultrasound workflow; outputs are assistive, can be Can't be analyzed, may be manually overridden, and cannot be the sole basis for management.

Clinical takeaway. Clinical role: Concurrent or post-exam fetal ultrasound aid that identifies and characterizes eight abnormal findings for interpreting-physician review; not the sole basis for management.

Evidence takeaway. Evidence from the reviewed source record: FDA bench testing used 8,745 images from 1,115 examinations at 75 sites and reported sensitivity 93.2% and specificity 90.8%; a separate 13-reader MRMC study used 750 images from 287 examinations at 47 sites and reported AUC 0.689 unassisted versus 0.909 assisted.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Concurrent or post-exam fetal ultrasound aid that identifies and characterizes eight abnormal findings for interpreting-physician review; not the sole basis for management.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Assistive concurrent or post-exam review; the interpreting physician retains responsibility and the output is not the sole basis for patient management.
  • Exact FDA submission
  • Checked 2026-09-06
Required input
Fetal ultrasound images and examination views from supported GE, Philips, Samsung and Canon systems, uploaded or connected through the workflow.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
Per-view statuses of Suspected, Not Suspected or Can't be analyzed for supported abnormal findings, with user ability to manually override the output.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Fetal ultrasound examinations from 11 through 41 weeks of gestation, during or after the examination.
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Physicians and trained healthcare professionals interpreting fetal ultrasound examinations.
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
The exact validation was limited to the specified ultrasound vendors and fetal ultrasound workflow; outputs are assistive, can be Can't be analyzed, may be manually overridden, and cannot be the sole basis for management.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
FDA bench testing used 8,745 images from 1,115 examinations at 75 sites and reported sensitivity 93.2% and specificity 90.8%; a separate 13-reader MRMC study used 750 images from 287 examinations at 47 sites and reported AUC 0.689 unassisted versus 0.909 assisted.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA bench testing used 8,745 images from 1,115 examinations at 75 sites and reported sensitivity 93.2% and specificity 90.8%; a separate 13-reader MRMC study used 750 images from 287 examinations at 47 sites and reported AUC 0.689 unassisted versus 0.909 assisted.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
93.2% (95% CI: 91.6%, 94.6%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
90.8% (95% CI: 89.5%, 92.0%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Abnormal-finding sensitivity

93.2 percent

  • EndpointBench abnormal-finding classification
  • Population8,745 fetal ultrasound images from 1,115 examinations at 75 sites
  • Tested versionSonio Suspect release reviewed in K243614

Abnormal-finding specificity

90.8 percent

  • EndpointBench abnormal-finding classification
  • Population8,745 fetal ultrasound images from 1,115 examinations at 75 sites
  • Tested versionSonio Suspect release reviewed in K243614

Reader AUC without assistance

0.689 AUC

  • EndpointReader abnormal-finding classification
  • Population13 readers reviewing 750 images from 287 examinations at 47 sites
  • Tested versionSonio Suspect release reviewed in K243614

Reader AUC with assistance

0.909 AUC

  • EndpointReader abnormal-finding classification
  • Population13 readers reviewing 750 images from 287 examinations at 47 sites
  • Tested versionSonio Suspect release reviewed in K243614

Sonio Suspect bench abnormal-finding validation

  • DesignRetrospective multi-site image-level validation
  • PopulationFetal ultrasound images from supported vendors and examinations at 11-41 weeks
  • Scopeexact submission
  • Tested versionSonio Suspect release reviewed in K243614
  • Samplen=8745
  • Sites75
  • IndependenceSponsor or vendor study

K243614 FDA 510(k) summary bench study

The FDA summary reports an independent dataset for the bench analysis and 64 U.S. sites among the 75 sites.

Sonio Suspect multi-reader multi-case study

  • Design13-reader multi-reader multi-case comparison of assisted and unassisted reading
  • Population250 positive and 500 negative fetal ultrasound images from 287 examinations at 47 sites
  • Scopeexact submission
  • Tested versionSonio Suspect release reviewed in K243614
  • Samplen=750
  • Sites47
  • IndependenceSponsor or vendor study

K243614 FDA 510(k) summary MRMC study

Readers included maternal-fetal medicine, obstetrics and gynecology, and radiology clinicians; the FDA summary reports AUC improvement with assistance.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Fetal ultrasound images and examination views from supported GE, Philips, Samsung and Canon systems, uploaded or connected through the workflow.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Sonio Suspect, K243614

  2. Routing

    Source context, not route validation: The current Sonio family platform page describes DICOM worklist and PACS/VNA integration, HL7/FHIR and EHR connectivity, and support across ultrasound manufacturers. The page's current clinical-AI footnote refers to Sonio Detect, so these family capabilities are not asserted as exact K243614 interfaces.

    Scope: Product family.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · Sonio clinical workflow and interoperability platform

  3. AI processing

    Source context, not route validation: The exact materials describe a SaaS web application accessible from an internet-connected tablet or computer during or after fetal ultrasound, with uploaded images or an ultrasound-system connection.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Sonio Suspect, K243614

  4. Returned objects

    Source context, not route validation: Per-view statuses of Suspected, Not Suspected or Can't be analyzed for supported abnormal findings, with user ability to manually override the output.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Sonio Suspect, K243614

  5. Viewer/worklist/report

    Unresolved route: Per-view statuses of Suspected, Not Suspected or Can't be analyzed for supported abnormal findings, with user ability to manually override the output.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for Sonio Suspect, K243614

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact materials describe a SaaS web application accessible from an internet-connected tablet or computer during or after fetal ultrasound, with uploaded images or an ultrasound-system connection.
  • Exact FDA submission
  • Checked 2026-09-06
Integration
The current Sonio family platform page describes DICOM worklist and PACS/VNA integration, HL7/FHIR and EHR connectivity, and support across ultrasound manufacturers. The page's current clinical-AI footnote refers to Sonio Detect, so these family capabilities are not asserted as exact K243614 interfaces.
  • Product family
  • Checked 2026-09-07
Security
Sonio's security page states HIPAA and GDPR compliance, HDS-certified cloud providers, SOC 2 Type 2 compliance, encryption at rest and in transit, a web application firewall with intrusion detection, and isolated regional deployments. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

SaaS access

The exact FDA materials describe a web application accessed from an internet-connected tablet or computer during or after the fetal ultrasound exam.

exact submission · checked 2026-09-06

Family interoperability

The current Sonio family page describes DICOM worklist/PACS/VNA, HL7/FHIR and EHR connections across ultrasound manufacturers; it does not establish exact K243614 interfaces and its clinical-AI footnote refers to Sonio Detect.

product family · checked 2026-09-07

Manual override and clinician control

The exact labeling permits the user to override the per-finding status, and current Sonio terms preserve physician judgment as the controlling boundary.

product family · checked 2026-09-07
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243614
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Obstetric/Fetal
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-02-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored candidate metadata contained empty PubMed and clinical-trial ID arrays; metadata was screened, not full-text or registry-reviewed. The stored recall candidate record was empty and no event was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor product page, vendor terms, peer reviewed publication, clinical trial registry, recall database, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No numeric price was published in the reviewed sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Sonio Suspect reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

10 sources - 3 history items

Source ledger

  1. K243614 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Sonio Suspect model card (K243614)

    American College of Radiology - Published 2026-07-08 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. FDA 510(k) decision record and summary reviewed for Sonio Suspect, K243614

    U.S. Food and Drug Administration - Published 2025-02-21 - Accessed 2026-09-06

    Scope: identity, intended_use, performance, limitations, implementation

  8. Sonio clinical workflow and interoperability platform

    Sonio - Accessed 2026-09-07

    Scope: product_family, cloud_workflow, DICOM_worklist, HL7_FHIR, ultrasound_integration

  9. Sonio Terms of Use

    Sonio - Accessed 2026-09-07

    Scope: product_family, Sonio_Suspect_purpose, limitations, account_terms, data_ownership

  10. Sonio Security and Medical Device Regulatory Info

    Sonio - Accessed 2026-10-25

    Scope: security

Research history

  1. K243614 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261519

Sonio Suspect

Sonio

Authorized purpose: Concurrent physician reading aid for specified abnormal fetal ultrasound findings; patient management must not rely solely on the analysis.

Modality
Ultrasound
Anatomy
Obstetric/Fetal
Decision
2026-06-04
FDA-cleared K252148

Butterfly Gestational Age Tool

Butterfly Network, Inc.

Authorized purpose: Butterfly Gestational Age Tool estimates gestational age for a singleton intrauterine pregnancy presumed to be 16 to 37 weeks within the labeled Butterfly ultrasound workflow; qualified professionals must review the output.

Modality
Ultrasound
Anatomy
Obstetric/Fetal
Decision
2026-03-27
FDA-cleared K250959

BioticsAI

Bioticsai, Inc.

Authorized purpose: BioticsAI assists healthcare professionals during and after fetal ultrasound acquisition and interpretation by detecting views and anatomical structures and facilitating quality-criteria verification on DICOM images and frames; it is a concurrent reading aid for the labeled GE ultrasound and prenatal population.

Modality
Ultrasound
Anatomy
Obstetric/Fetal
Decision
2025-12-22

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history